The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

Shares of Biogen Inc. BIIB slid 1.10% to $142.34 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.76% to 5,994.57 and Dow ...

Biogen BIIB and Japan-based partner, Eisai, announced an update regarding the regulatory review of an application seeking the ...

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...

Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

Sage’s board of directors said Biogen’s offer “undervalues” the company, but will explore other strategic alternatives to ...

Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...

Biogen has been in the news recently after longtime partner Sage Therapeutics filed a lawsuit against the company after ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...